A Quick Fix? Short-Term CXCR4 Inhibition Redistributes Pro-Angiogenic Bone Marrow Cells to Ischemic Myocardium in an eNOS-Dependent Fashion
Autologous cell therapy with bone marrow (BM)-derived pro-angiogenic cells is a promising new treatment modality to enhance ischemic recovery after myocardial infarction. However, the introduction into the clinical mainstream is hampered by technical challenges with cell procurement, handling, selection, expansion and application. In this issue of Circulation, Jujo et al. show that mobilization of endogenous cells by a clinically approved drug inhibiting the CXCR4 receptor improves myocardial recovery after infarction in a mouse model of ischemia/reperfusion (IR).1
- Received November 23, 2012.
- Accepted November 27, 2012.
- Copyright © 2012, American Heart Association, Inc. All rights reserved. Unauthorized use prohibited